Skip to main content
TipRanks
Go Ultimate75% OFF

Elevance Health (A58) AI Stock Analysis

1 Followers
CH:A58

Elevance Health

(BX Swiss:A58)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong Cash GenerationElevance’s strong cash conversion provides internal funding for investments, capital returns, and balance-sheet needs. The $6.5 billion TTM free-cash-flow recovery indicates substantial earnings support, although continued monitoring is warranted because cash conversion has varied across years.
Negative Factors
Margin CompressionPersistent margin compression reduces the earnings benefit of revenue growth and leaves less room for adverse medical-cost or pricing developments. Lower operating profitability also makes execution in Medicaid, Medicare Advantage, and commercial products more important to sustained returns.

Elevance Health (A58) vs. iShares MSCI Switzerland ETF (EWL)

-5%0%5%10%15%20%25%CH:A580.00%EWL+11.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CHF 85.23B
Dividend Yield
1.48%
Average Volume (3M)
4
Price to Earnings (P/E)
16.8
Beta (1Y)
-0.34
Revenue Growth
-2.90%
EPS Growth
-10.62%
Country
Switzerland
Employees
96,615
Sector
Healthcare
Sector Strength
51
Industry
Medical - Healthcare Plans

Elevance Health Business Overview & Revenue Model

Company Description

Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enabl...

Elevance Health Earnings Call Summary

Earnings Call Date:Oct 21, 2026(Q3-2026)|Next Earnings Date:Jan 27, 2027
Earnings Call SentimentPositive

The call was strongly positive. Elevance Health reported better-than-expected third-quarter results, raised 2026 adjusted EPS guidance to at least $29, increased its earnings baseline to at least $26.75, raised operating cash flow guidance to at least $6.5 billion, and maintained confidence in at least 12% adjusted EPS growth in 2027. Medicaid cost trends, commercial cost pressures, IDR-related issues, ACA risk-pool normalization, and a non-recurring fourth-quarter tax item remain challenges, but management characterized operating performance and visibility as improving across the enterprise.

Positive Updates

Raised 2026 Earnings Guidance and Higher Earnings Baseline
Elevance Health raised 2026 adjusted diluted earnings per share guidance to at least $29. The 2026 earnings baseline increased by $0.75 to at least $26.75, reflecting third-quarter operating outperformance and an improved full-year outlook for Individual ACA.

Negative Updates

Elevated Medicaid Cost Trend
Medicaid cost trend remained elevated, although management described it as relatively stable compared with the second quarter. Rates have improved but have not fully caught up with the underlying cost of care.

Company Guidance

Elevance Health raised 2026 adjusted diluted earnings per share guidance to at least $29 and its 2026 earnings baseline to at least $26.75, and remains confident in delivering at least 12% adjusted diluted earnings per share growth in 2027; Medicaid margins are expected to improve in 2027, with a long-term margin target of 2%-4%, Medicare Advantage is expected to deliver a full-year operating margin of at least 2% in 2026 and move toward a long-term target margin range of 3%-5%, Individual ACA is expected to have a modestly higher full-year operating margin and end 2026 with at least 1.2 million members, full-year operating cash flow guidance was raised to at least $6.5 billion, Commercial Group cost trend for 2026 and 2027 was priced for a low double-digit cost trend environment, and the risk pool is expected to take more than one renewal cycle to normalize following the expiration of those enhanced subsidies.

Elevance Health Risk Analysis

Elevance Health disclosed 28 risk factors in its most recent earnings report. Elevance Health reported the most risks in the "Ability to Sell" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Ability to Sell - Risks related to the company’s ability to sell goods and services

Latest Risks Added

0 New Risks

Elevance Health Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CH:A58 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CICI75Outperform$71.95B11.9214.10%2.28%6.79%-0.38%
CVSCVS71Outperform$102.41B9.3314.13%3.29%6.77%2114.64%
CNCCNC68Neutral$32.47B21.556.78%―9.71%―
UNHUNH67Neutral$296.12B19.4016.35%2.67%3.33%-8.75%
HUMHUM55Neutral$45.64B37.566.70%0.91%22.02%-3.07%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%CH:A58CNCCICVSHUMUNHDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:A58 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CH:A58Elevance Health, Inc.369.860.000.00%
CNCCentene63.7825.6167.09%
CICigna270.905.452.05%
CVSCVS Health Corp80.845.266.96%
HUMHumana390.00163.7572.38%
UNHUnitedhealth Group Inc.339.8529.089.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.